New therapeutic approaches to hepatitis C virus
نویسندگان
چکیده
منابع مشابه
Hepatitis C virus and skin
Nowadays viral hepatitis is one of the most common and important causes of chronic liver disorders in the world. Extrahepatic manifestations of viral hepatitis consist a main part of the disease. The main viruses causing hepatitis include Hepatitis A, B and C viruses. Herein common skin manifestations in hepatitis C virus (HCV) are discussed. Chronic hepatitis causes skin disorders both directl...
متن کاملVirus-induced Systemic Vasculitides: New Therapeutic Approaches
The best therapeutic strategy in virus-induced vasculitides should take into account the etiology of the disease and be adapted to the pathogenesis. The combination of antiviral treatments and plasma exchanges has been proven effective in polyarteritis nodosa (PAN). In human immunodeficiency virus (HIV)-related vasculitis this strategy is also effective and does not jeopardize, like cytotoxic a...
متن کاملHepatitis C Virus: A Critical Appraisal of New Approaches to Therapy
The HCV council 2011 convened 11 leading clinicians and researchers in hepatitis C virus from academic medical centers in the United States to provide a forum for the practical and comprehensive evaluation of current data regarding best practices for integrating new direct-acting antiviral agents into existing treatment paradigms. The council investigated 10 clinical practice statements related...
متن کاملThe Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase Inhibitors
The current standard of care for hepatitis C infection is peginterferon/ribavirin (PegIFN/RBV). We are entering the era where direct-acting antiviral agents (DAAs) will be added to PegIFN/RBV, leading to higher sustained response rates in genotype 1 infected individuals. Currently DAAs are directed toward specific proteins involved in hepatitis C replication with NS3/NS4A protease inhibitors fu...
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Gastroenterology
سال: 2009
ISSN: 0944-1174,1435-5922
DOI: 10.1007/s00535-009-0084-0